

Please type a plus sign (+) inside this box +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>		<b>Complete if Known</b>	
		Application Number	10/665,449
		Filing Date	September 22, 2003
		First Named Inventor	Alfred WEBER et al.
		Group Art Unit	1656
		Examiner Name	KAM, Chih M.
		Attorney Docket Number	JS-0060-C01
Sheet	1		2

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	1	BRENNEMAN ET AL., "Effect of dietary fat saturation on acylcoenzyme A: cholesterol acyltransferase activity of Ehrlich cell microsomes." Journal of Lipid Research, Vol. 18, 582-591, September 1977	
	2	BENNETZEN ET AL., "The primary structure of the Saccharomyces cerevisiae gene for alcohol dehydrogenase." J. Biol. Chem., Vol. 257, Issue 6, 3018-3025, Mar, 1982	
	3	FAVRE ET AL., "Characterization of squalene epoxidase activity from the dermatophyte Trichophyton rubrum and its inhibition by terbinafine and other antimycotic agents." Antimicrobial Agents and Chemotherapy, 02 1996, 443-447, Vol 40, No. 2	
	4	ROBINSON ET AL., "Conservation between human and fungal squalene synthetases: similarities in structure, function, and regulation." Mol Cell Biol. 1993 May; 13(5): 2706-2717	
	5	GEORGOPAPADAKOU ET AL., "Effects of squalene epoxidase inhibitors on Candida albicans." Antimicrob Agents Chemother. 1992 August; 36(8): 1779-1781	
	6	JANDROSITZ ET AL., "The gene encoding squalene epoxidase from Saccharomyces cerevisiae : cloning and characterization." Gene. 1991 Oct 30;107(1):155-60.	
	7	JENNINGS ET AL., "Molecular cloning and characterization of the yeast gene for squalene synthetase." PNAS July 15, 1991 vol. 88 no. 14 6038-6042	
	8	NAGUMO ET AL., "Purification and characterization of recombinant squalene epoxidase." Journal of Lipid Research, Vol 36, 1489-1497	
	9	HSIUNG ET AL., "Squalene Epoxidase of Rat Liver." J. Biol. Chem. 1972 247: 3767-3773.	
	10	NAKASHIMA ET AL., "Cloning, expression, and characterization of cDNAs encoding Arabidopsis thaliana squalene synthase." PNAS March 14, 1995 vol. 92 no. 6 2328-2332	
	11	ROBINSON ET AL., "Conservation between human and fungal squalene synthetases: similarities in structure, function, and regulation." Mol Cell Biol. 1993 May ;13 (5):2706-17	
	12	WEILAND ET AL., "Genetic and biochemical analyses of the biosynthesis of the yellow carotenoid 4,4'-diaponeurosporene of Staphylococcus aureus." J Bacteriol. 1994 December; 176(24): 7719-7726	
	13	LINDSEY ET AL., "Inhibition of Mammalian Squalene Synthetase Activity by Zaragozic Acid A Is a Result of Competitive Inhibition Followed by Mechanism-based Irreversible Inactivation." J. Biol. Chem., Vol. 270, Number 16, Issue of April 21, pp. 9083-9096, 1995	
	14	FEQUEUR ET AL., "Isolation and primary structure of the ERG9 gene of Saccharomyces cerevisiae encoding squalene synthetase." Curr Genet. 1991 Nov;20(5):365-72	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

<sup>1</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

<b>Substitute for form 1449A/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>		<b>Complete if Known</b>			
		Application Number	10/665,449		
		Filing Date	September 22, 2003		
		First Named Inventor	Alfred WEBER et al.		
		Group Art Unit	1656		
		Examiner Name	KAM, Chih M.		
Sheet	2		2	Attorney Docket Number	JS-0060-C01

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	15	BERGSTROM ET AL., "Zaragozic acids: a family of fungal metabolites that are picomolar competitive inhibitors of squalene synthase." PNAS January 1, 1993 vol. 90 no. 1 80-84	
	16	CIOSEK ET AL., "Lipophilic 1,1-bisphosphonates are potent squalene synthase inhibitors and orally active cholesterol lowering agents in vivo." J. Biol. Chem., Vol. 268, Issue 33, 24832-24837, 11, 1993	
	17	BISCHOFF ET AL., "3-Hydroxy-3-methylglutaryl-coenzyme A reductase from Haloferax volcanii: purification, characterization, and expression in Escherichia coli." J. Bacteriol., Jan 1996, 19-23, Vol 178, No. 1	
	18	BOCHAR ET AL., "3-hydroxy-3-methylglutaryl coenzyme A reductase of Sulfolobus solfataricus: DNA sequence, phylogeny, expression in Escherichia coli of the hmgA gene, and purification and kinetic characterization of the gene product." J. Bacteriol., Jun 1997, 3632-3638, Vol 179, No. 11	
	19	PENA-DIAZ ET AL., "A soluble 3-hydroxy-3-methylglutaryl-CoA reductase in the protozoan Trypanosoma cruzi." J. Bacteriol., Jun 1997, 3632-3638, Vol 179, No. 11	
	20	BASSON ET AL., "Structural and functional conservation between yeast and human 3-hydroxy-3-methylglutaryl coenzyme A reductases, the rate-limiting enzyme of sterol biosynthesis." Mol Cell Biol. 1988 September; 8(9): 3797-3808	
	21	MEINER ET AL., "Disruption of the acyl-CoA:cholesterol acyltransferase gene in mice: Evidence suggesting multiple cholesterol esterification enzymes in mammals." PNAS November 26, 1996 vol. 93 no. 24 14041-14046	
	22	YANG ET AL., "Functional Expression of a cDNA to Human Acyl-coenzyme A:Cholesterol Acyltransferase in Yeast." Mol Cell Biol. 1988 September; 8(9): 3797-3808	
	23	YU ET AL., "Molecular Cloning and Characterization of Two Isoforms of Saccharomyces cerevisiae Acyl-CoA:Sterol Acyltransferase." J. Biol. Chem., Vol. 271, Number 39, Issue of September 27, 1996 pp. 24157-24163	
	24	MARZETTA ET AL., "Pharmacological properties of a novel ACAT inhibitor (CP-113,818) in cholesterol-fed rats, hamsters, rabbits, and monkeys." Journal of Lipid Research, Vol 35, 1829-1838	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

<sup>1</sup> EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.